|Year to Date: $409.67M|
Elanco Animal Health (unit of Eli Lilly and Co.)
Triggered by the the granting of a patent in Europe covering Acrux's drug delivery technology; Elanco has rights in animal health applications (5/8)
Merck & Co. Inc.
Triggered by Merck's initiation of a Phase II trial of MK-0354, an Arena- discovered candi-date being developed for treating atherosclerosis and related disorders (5/18)
Novartis Pharma AG (Switzerland)
Triggered by Novartis' decision to initiate development of an oral human growth hormone product using Emisphere's eligen delivery technology (5/1)
GlaxoSmithKline plc (UK)
Triggered by successful completion of activities related to the manufacturing process for Coreg CR microparticles, under their December 2004 supply agreement (5/19)
F. Hoffmann-La Roche Ltd. (Switzerland)
The preclinical milestone was triggered by Maxygen's development of a manufacturing process for Factor VIIa product candidates (5/9)
Astellas Pharma Inc. (Japan)
Payments were triggered by Astellas' initiation of a high-throughput screen on a previously selected target from their collaboration, and its choice of an additional target for screening (5/25)
Triggered by Pfizer's selection of R343 for advanced preclinical development in allergic asthma, from their 2005 collaboration on syk kinase inhibitors (5/17)
MGI Pharma Inc. (MOGN)
Triggered by MGI's first commercial shipment of the recently approved drug Dacogen (5/26)
Teva Pharmaceuticals Industries Ltd. (Israel)
Triggered by successful completion of the first clinical trials from their deal dating back to 2004 (5/1)
# Unless otherwise indicated, shares are traded on the Nasdaq exchange.
* Private company.
Currency conversions are based on exchange rates at the time of the deal.
ND = Not disclosed.
ASX = Australian Stock Exchange.